Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024
March 08, 2024 01:30 ET
|
CROSSJECT
Dijon, France, 08 mars 2024 – 07:30 CET - Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), une société pharmaceutique spécialisée qui développe des auto-injecteurs sans aiguille dédiés aux...
Crossject gender equality score reaches 96/100 in 2024
March 08, 2024 01:30 ET
|
CROSSJECT
Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today...
Rising fears of needlestick injuries and preference for painless options propel the needle-free injection system market towards a US$ 667 million valuation by 2034 | FMI Study
March 04, 2024 08:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 04, 2024 (GLOBE NEWSWIRE) -- Future Market Insights anticipated that the global needle-free injection systems market size is going to reach US$ 667 million by 2034, up from US$...
Crossject obtient un financement jusqu’à 12 millions d’euros en 2 tranches
February 27, 2024 02:30 ET
|
CROSSJECT
Dijon, le 27 février 2024 à 08h30 Crossject obtient un financement jusqu’à 12 millions d’euros en 2 tranches, auprès d’une entité gérée par Heights Capital Management, sous forme d’émission...
Crossject obtains a financing up to €12 million, in two tranches
February 27, 2024 02:30 ET
|
CROSSJECT
Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to €12 million, in two tranches,from an entity managed by Heights Capital Management, in issued bondsconvertible in new shares,...
Crossject publie une mise à jour stratégique de ses priorités pour 2024
February 06, 2024 11:30 ET
|
CROSSJECT
Priorité aux dépôts réglementaires et accélération des efforts de commercialisation aux États-Unis Avancées dans le déroulé du contrat avec la BARDA, d'une valeur maximale de 155 millions de dollars,...
Crossject provides strategic update on priorities for 2024
February 06, 2024 11:30 ET
|
CROSSJECT
Focusing on regulatory filings and accelerating U.S. commercialization efforts Contract of up to $155 million with BARDA for U.S. stockpiling continues to advance Dijon, France February 6, 2024 –530...
Crossject organisera un webcast le 6 février à 17h30 pour faire le point sur sa stratégie commerciale
February 01, 2024 12:15 ET
|
CROSSJECT
Dijon, France, 1 février 2024 – 18 : 15 CET - Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), une société pharmaceutique spécialisée qui développe des auto-injecteurs sans aiguille dédiés aux...
Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET
February 01, 2024 12:15 ET
|
CROSSJECT
Dijon, France, February 1, 2024 -- 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a...
Global Needle-Free Drug Delivery Devices Market Analysis, 2024-2034, Dominated by PharmaJet, Halozyme (Antares Pharma), Crossject, 3M, and PenJet Corporation
January 24, 2024 14:17 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Needle-Free Drug Delivery Devices Market Analysis & Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The...